Identifying a Potential Drug Candidate for Human Testing in 90 Days
AbCellera’s CEO, Carl Hansen, Ph.D., gave a keynote presentation at the AWS Healthcare & Life Sciences Web Day 2020.
AbCellera’s technology and teams can quickly scan, decode, and analyze antibodies from natural immune systems to discover antibodies that can potentially be developed into novel treatments. In collaboration with Eli Lilly and Company, AbCellera’s rapid pandemic response platform has contributed to the world’s first COVIDcampaign-pages/bispecifics/-19 clinical trial for a potential monoclonal antibody treatment.
Full coverage on AWS Healthcare & Life Sciences Web Day.